UEEC's Net Loss Doubles Amid Zero Revenue, Cash Dries Up

TL;DR

**UEEC is burning cash at an alarming rate with no revenue in sight; steer clear unless you're betting on a miracle.**

AI Summary

United Health Products, Inc. (UEEC) reported no revenue for the three and six months ended June 30, 2025, continuing its pre-revenue status. The company's net loss significantly widened to $1,846,846 for the six months ended June 30, 2025, compared to a net loss of $883,959 for the same period in 2024, representing a 108.9% increase. This was primarily driven by a substantial rise in selling, general and administrative expenses, which surged from $648,999 in H1 2024 to $1,560,338 in H1 2025. Research and development expenses also increased to $197,234 in H1 2025 from $181,272 in H1 2024. Cash and cash equivalents plummeted from $168,883 at December 31, 2024, to a mere $225 by June 30, 2025. The company's total liabilities grew to $3,252,090 from $2,713,810, while its stockholders' deficit deepened to $(3,170,552) from $(2,443,831). UEEC continues to rely on equity sales and traditional financing to fund operations, with substantial doubt about its ability to continue as a going concern.

Why It Matters

This 10-Q filing paints a grim picture for United Health Products, Inc., highlighting its continued inability to generate revenue while operating expenses escalate. For investors, the substantial doubt about the company's going concern status and the near-depletion of cash reserves to just $225 are critical red flags, indicating significant financial instability and a high risk of further dilution or bankruptcy. Employees face uncertainty regarding job security given the company's precarious financial health. Customers, particularly those awaiting the CelluSTAT product's regulatory approval for U.S. Class III surgical markets, may experience delays or a complete halt in product availability if the company cannot secure further funding. In a competitive healthcare and wound care sector, UEEC's lack of commercialization and deepening losses make it an increasingly vulnerable player.

Risk Assessment

Risk Level: high — The company explicitly states "there is substantial doubt about the Company's ability to continue as a going concern" due to recurring net losses, negative working capital, and insufficient revenue-producing operations. Cash and cash equivalents have dwindled to $225 as of June 30, 2025, from $168,883 at December 31, 2024, indicating severe liquidity issues.

Analyst Insight

Investors should exercise extreme caution and consider divesting any holdings in UEEC. The company's pre-revenue status, rapidly depleting cash, and explicit going concern warning suggest a high probability of further share dilution or potential bankruptcy. Avoid initiating new positions.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

$71,538

total Debt

$3,252,090

net Income

$(1,846,846)

eps

N/A

gross Margin

N/A

cash Position

$225

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (No revenue generated for the three and six months ended June 30, 2025 and 2024.)
• $(1.85M) — Net Loss (Six Months) (Increased 108.9% from $(0.88M) in H1 2024 to $(1.85M) in H1 2025.)
• $225 — Cash and Cash Equivalents (Dramatic decrease from $168,883 at Dec 31, 2024, indicating severe liquidity issues.)
• $1.56M — SG&A Expenses (Six Months) (Increased from $0.65M in H1 2024, contributing to wider net loss.)
• $(3.17M) — Stockholders' Deficit (Deepened from $(2.44M) at Dec 31, 2024, reflecting accumulated losses.)
• 257,733,222 — Common Shares Outstanding (As of August 14, 2025, indicating potential for further dilution.)
• $3.25M — Total Liabilities (Increased from $2.71M at Dec 31, 2024, adding to financial strain.)

Key Players & Entities

• United Health Products, Inc. (company) — developer, manufacturer, and marketer of hemostatic gauze
• CelluSTAT (product) — patented hemostatic gauze product
• SEC (regulator) — Securities and Exchange Commission
• $1,846,846 (dollar_amount) — net loss for the six months ended June 30, 2025
• $883,959 (dollar_amount) — net loss for the six months ended June 30, 2024
• $225 (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $168,883 (dollar_amount) — cash and cash equivalents as of December 31, 2024
• $1,560,338 (dollar_amount) — selling, general and administrative expenses for the six months ended June 30, 2025
• $648,999 (dollar_amount) — selling, general and administrative expenses for the six months ended June 30, 2024
• $3,170,552 (dollar_amount) — total stockholders' deficit as of June 30, 2025

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company has incurred significant net losses, with a loss of $1,846,846 for the six months ended June 30, 2025, and its cash and cash equivalents have dwindled to $225 as of June 30, 2025. This raises substantial doubt about its ability to continue as a going concern.
• Deteriorating Liquidity [high — financial]: Cash and cash equivalents decreased from $168,883 at December 31, 2024, to $225 at June 30, 2025. This severe liquidity crunch limits the company's operational flexibility and ability to meet short-term obligations.
• Increasing Liabilities and Deficit [high — financial]: Total liabilities increased to $3,252,090 as of June 30, 2025, from $2,713,810 at December 31, 2024. Concurrently, the stockholders' deficit widened to $(3,170,552), indicating a deteriorating financial position.
• High Operating Expenses [medium — operational]: Selling, general and administrative expenses surged by 140.4% to $1,560,338 for the six months ended June 30, 2025, from $648,999 in the prior year period. Research and development expenses also increased to $197,234. These rising costs contribute significantly to the net loss.
• Reliance on Equity Financing [medium — financial]: The company continues to rely on equity sales and traditional financing to fund operations. With no revenue and a precarious cash position, future funding remains uncertain and could lead to significant dilution for existing shareholders.

Industry Context

United Health Products, Inc. operates in a highly competitive healthcare and medical products sector. The industry is characterized by rapid technological advancements, stringent regulatory oversight (e.g., FDA approvals), and significant R&D investment requirements. Companies often face challenges in achieving profitability, especially in early stages, and rely on innovation and market penetration to succeed.

Regulatory Implications

As a company in the health products sector, UEEC is subject to rigorous regulatory scrutiny from bodies like the FDA. Any product development or commercialization efforts would require extensive compliance and approval processes, which can be time-consuming and costly, posing a significant risk if not managed effectively.

What Investors Should Do

1. Monitor cash burn rate closely.
2. Scrutinize any future financing announcements.
3. Evaluate the viability of the company's business model and product pipeline.

Key Dates

• 2025-06-30: End of Second Quarter — Reported $0 revenue and a significantly widened net loss of $1,846,846 for the six-month period. Cash position drastically reduced to $225.
• 2024-12-31: End of Fiscal Year — Company had $168,883 in cash and cash equivalents and total liabilities of $2,713,810.

Glossary

Stockholders' Deficiency

A negative amount in the stockholders' equity section of the balance sheet, indicating that a company's liabilities exceed its assets. (UEEC's stockholders' deficit widened to $(3,170,552), highlighting its negative net worth and financial distress.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (Substantial doubt exists about UEEC's ability to continue as a going concern due to its financial condition, including lack of revenue and severe cash shortage.)

Selling, General and Administrative Expenses (SG&A)

Costs incurred by a company for marketing, advertising, sales, and administrative functions, excluding research and development costs. (UEEC's SG&A expenses more than doubled in H1 2025, significantly contributing to the increased net loss.)

Year-Over-Year Comparison

Compared to the prior year period, United Health Products, Inc. has seen a dramatic deterioration in its financial standing. Revenue remains at $0, but the net loss has more than doubled, increasing by 108.9% to $1,846,846 for the six months ended June 30, 2025. This widening loss is primarily driven by a substantial increase in SG&A expenses, which surged by 140.4%. The company's cash position has collapsed from $168,883 at year-end 2024 to a critical $225, while total liabilities have grown, and the stockholders' deficit has deepened, underscoring severe financial strain and heightened going concern risks.

Key Financial Figures

• $0.35 — rity date at a price that is lower than $0.35 per share, the conversion price shall b

Filing Documents

• ueec_10q.htm (10-Q) — 638KB
• ueec_ex311.htm (EX-31.1) — 10KB
• ueec_ex312.htm (EX-31.2) — 10KB
• ueec_ex321.htm (EX-32.1) — 5KB
• ueec_ex322.htm (EX-32.2) — 5KB
• 0001477932-25-005894.txt ( ) — 3242KB
• ueec-20250630.xsd (EX-101.SCH) — 35KB
• ueec-20250630_lab.xml (EX-101.LAB) — 237KB
• ueec-20250630_cal.xml (EX-101.CAL) — 34KB
• ueec-20250630_pre.xml (EX-101.PRE) — 189KB
• ueec-20250630_def.xml (EX-101.DEF) — 94KB
• ueec_10q_htm.xml (XML) — 374KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) Condensed Balance Sheets as of June 30, 2025 (unaudited) and December 31, 2024 3 Condensed Statements of Operations for the Three and Six Months Ended June 30, 2025 and June 30, 2024 (unaudited) 4 Condensed Statement of Stockholders' Deficiency for the Three and Six Months Ended June 30, 2025 and June 30, 2024 (unaudited) 5 Condensed Statements of Cash Flows for the Six Months Ended June 30, 2025 and June 30, 2024 (unaudited) 6 Notes to Condensed Financial Statements (unaudited) 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 17 Item 3.

Quantitative and Qualitative Disclosures

Quantitative and Qualitative Disclosures 24 Item 4.

Controls and Procedures

Controls and Procedures 24

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 25 Item 1A.

Risk Factors

Risk Factors 25 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 25 Item 3. Defaults Upon Senior Securities 25 Item 4. Mine Safety Disclosures 25 Item 5. Other Information 25 Item 6. Exhibits 26

SIGNATURES

SIGNATURES 27 2 Table of Contents UNITED HEALTH PRODUCTS, INC. Condensed Balance Sheets June 30, December 31, 2025 2024 (Unaudited) ASSETS Current Assets Cash and cash equivalents $ 225 $ 168,883 Prepaid and other current assets 20,886 22,800 Total current assets 21,111 191,683 Operating lease right-of-use asset 31,252 47,096 Security deposit 2,850 2,850 Patents, net 26,325 28,350 TOTAL ASSETS $ 81,538 $ 269,979 Current Liabilities Accounts payable and accrued expenses $ 956,206 $ 830,672 Accrued liabilities - related parties 212,111 168,649 Accrued compensation 703,738 608,500 Operating lease liability - current 32,535 33,331 Total current liabilities 1,904,590 1,641,152 Convertible notes payable, net of debt discount 847,500 557,500 Convertible notes payable – related party, net of debt discount 500,000 500,000 Operating lease liability – long-term - 15,158 TOTAL LIABILITIES 3,252,090 2,713,810 Commitments and Contingencies - - Stockholders' Deficit Series A Convertible Preferred Stock - $ 0.001 par value, 1,000,000 shares Authorized and 0 shares issued and outstanding - - Common Stock - $ 0.001 par value, 300,000,000 shares Authorized, 257,333,222 and 252,408,222 shares issued and outstanding at June 30, 2025 and December 31, 2024 257,333 252,408 Subscription Receivable ( 16,570 ) - Additional Paid-In Capital 77,136,474 76,004,704 Accumulated Deficit ( 80,547,789 ) ( 78,700,943 ) Total Stockholders' Deficit ( 3,170,552 ) ( 2,443,831 ) TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT $ 81,538 $ 269,979 See notes to unaudited condensed financial statements. 3 Table of Contents UNITED HEALTH PRODUCTS, INC. Condensed Statements of Operations (Unaudited) For the Three Months Ended June 30, For the Six Months Ended June 30, 2025 2024 2025 2024 Revenues $ - $ - $ - $ - Operating Costs and E

View Full Filing

View this 10-Q filing on SEC EDGAR